Apollomics Inc.

Apollomics Inc.

Apollomics was founded in 2015 by Guo-Liang Yu, a veteran biotech entrepreneur who previously co-founded Epitomics and later served as CEO of Crown Bioscience. The firm operates at the intersection of computational biology and clinical development, using machine learning models to identify novel therapeutic applications for compounds that have already passed Phase I safety trials. This approach targets the high failure rate in oncology by starting with molecules that have established human safety profiles, then matching them to underserved cancer indications through systematic screening. The firm's core strategy centers on acquiring or licensing shelved clinical-stage assets and deploying its AI platform to match them with new oncology targets. Apollomics has advanced a pipeline that includes vebreltinib, a c-MET inhibitor licensed for development in non-small cell lung cancer and other solid tumors with MET alterations, and uproleselan, an E-selectin antagonist being evaluated in acute myeloid leukemia. The model spans asset sourcing, computational validation, and clinical execution, with trials conducted in both the United States and China through partnerships with academic medical centers and contract research organizations. Apollomics went public in March 2023 through a merger with Maxpro Capital Acquisition Corp., a special-purpose acquisition company, with the combined entity trading on Nasdaq under the ticker APLM. The de-SPAC transaction provided capital to advance its lead programs toward registrational trials, though the company has since faced the same post-merger cash constraints common among biotech SPACs. As a public reporting company, Apollomics discloses its clinical milestones and financial position through SEC filings, but it does not operate as a traditional investment manager with external limited partners or discretionary AUM. Structurally, Apollomics differs from a conventional biotech in its systematic repurposing thesis: rather than originating novel molecules, it functions as a matchmaker between existing drug candidates and computationally identified disease targets. This places it closer to a drug-development platform company than a family office or fund manager. Yu's leadership team combines experience from Epitomics, CrownBio, and global pharma, creating continuity across antibody development, preclinical modeling, and translational oncology.